Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR Fellowship

Direct Payment

$141,667.00

Cardiac-derived stem cell therapy to treat dystrophic cardiomyopathy

FY 2012-13

Summary
Duchenne muscular dystrophy (DMD) is a devastating X-linked muscle wasting disease for which there is no specific treatment. Affecting 1 in 3,500 male births, DMD accounts for 80% of all cases of muscular dystrophy. Boys are diagnosed as toddlers and most are wheelchair bound by age 15. Death often occurs by age 20 from respiratory muscle weakness and cardiomyopathy. More patients are surviving to age 30 thanks to non-invasive home ventilation and corticosteroids, which can prolong ambulation by 2-3 years, reduce the risk of scoliosis, and temper pulmonary decline in the second decade. Corticosteroids are no panacea however, and cause much toxicity; aprroximetly 28% of boys develop intolerable side-effects. A therapeutic breakthrough is therefore urgently needed. Investigational therapies aim to: (1) increase muscle mass and regeneration, (2) decrease muscle inflammation and fibrosis, (3) correct perturbations in cellular calcium handling, or (4) correct abnormal blood flow regulation. We postulate that stem cell derived from the heart, could simultaneously address all of these therapeutic targets. Indeed, cardiac-derived stem cells have been shown to regenerate heart muscle, reduce inflammation and fibrosis, and grow new blood vessels in common ischemic heart disease, thus restoring normal cardiac function. We now hypothesize that cardiac-derived stem cells constitute an effective novel therapy for the heart in DMD.
Program
CIHR Fellowship
Location
California, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
281540
Name
Nelson Michael D
Region
California
Country
United States of America
Orgtype
Research Institution
Instname2
Musculoskeletal Health and Arthritis
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Cardiac-derived stem cell therapy to treat dystrophic cardiomyopathy
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$141,667
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Cardiac Derived Stem Cells; Duchenne Cardiomyopathy; Muscular Dystrophy
Abstract
Duchenne muscular dystrophy (DMD) is a devastating X-linked muscle wasting disease for which there is no specific treatment. Affecting 1 in 3,500 male births, DMD accounts for 80% of all cases of muscular dystrophy. Boys are diagnosed as toddlers and most are wheelchair bound by age 15. Death often occurs by age 20 from respiratory muscle weakness and cardiomyopathy. More patients are surviving to age 30 thanks to non-invasive home ventilation and corticosteroids, which can prolong ambulation by 2-3 years, reduce the risk of scoliosis, and temper pulmonary decline in the second decade. Corticosteroids are no panacea however, and cause much toxicity; aprroximetly 28% of boys develop intolerable side-effects. A therapeutic breakthrough is therefore urgently needed. Investigational therapies aim to: (1) increase muscle mass and regeneration, (2) decrease muscle inflammation and fibrosis, (3) correct perturbations in cellular calcium handling, or (4) correct abnormal blood flow regulation. We postulate that stem cell derived from the heart, could simultaneously address all of these therapeutic targets. Indeed, cardiac-derived stem cells have been shown to regenerate heart muscle, reduce inflammation and fibrosis, and grow new blood vessels in common ischemic heart disease, thus restoring normal cardiac function. We now hypothesize that cardiac-derived stem cells constitute an effective novel therapy for the heart in DMD.
Competitiondate
201302
Approvedterm2
2 yrs 10 mths
Pinamesdelim
Nelson, Michael D
Approvedterm
2 ans 10 mois
Cihrcontribution2
~ $141,667~ $0~